Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported Licence

Self-quenched ferrocenyl diketopyrrolopyrrole organic nanoparticles with amplifying photothermal effect for cancer therapy

Pingping Liang a, Qianyun Tang a, Yu Cai a, Gongyuan Liu a, Weili Si a, Jinjun Shao a, Wei Huang *a, Qi Zhang *b and Xiaochen Dong *a
aKey Laboratory of Flexible Electronics (KLOFE), Institute of Advanced Materials (IAM), Jiangsu National Synergetic Innovation Center for Advanced Materials (SICAM), Nanjing Tech University (NanjingTech), 30 South Puzhu Road, Nanjing 211816, China. E-mail:;
bSchool of Pharmaceutical Sciences, Nanjing Tech University (NanjingTech), Nanjing, China. E-mail:

Received 1st August 2017 , Accepted 4th September 2017

First published on 5th September 2017

Organic nanoparticles (NPs) with near-infrared absorbance possess high photothermal conversion (PTC) efficiency and an excellent photoacoustic signal, presenting a great prospect for photoacoustic imaging (PAI)-guided photothermal therapy (PTT). Herein, a novel diketopyrrolopyrrole derivative (DPPCN-Fc) is synthesized for use as a PTT agent with PAI performance. Due to photo-induced electron transfer (PET), the two flanked ferrocene moieties significantly quench the radiative decay and intersystem crossing process, resulting in an enhanced nonradiative transition, and an amplifying photothermal effect is observed. Exposing the DPPCN-Fc NP aqueous dispersion (100 μg mL−1) to 730 nm (1.0 W cm−2) laser radiation results in a temperature elevation of 33.4 °C within 10 min and the PTC efficiency reaches up to 59.1%, which is higher than most reported photothermal therapeutic agents. Furthermore, under irradiation from 730 nm lasers, cancer cells could be completely killed in vivo due to the amplifying photothermal effects. Therefore, the as-prepared DPPCN-Fc NPs are a promising cancer theranostic agent for photoacoustic imaging-guided cancer photothermal therapy.


Cancer has become one of the major threats to human health in modern society, although great effort has been made toward its treatment.1 Traditional treatments, including surgery, hormone therapy, immunotherapy, radiotherapy and chemotherapy, all have their intrinsic limits, such as drug resistance, side effects, low targeting and lack of specificity for individual cancer patients.2–7 Photothermal therapy (PTT), a highly selective and noninvasive therapeutic method with near-infrared (NIR) laser-induced ablation of tumor cells, has recently emerged among the many treatments to show great promise for cancer treatment and accordingly has attracted great attention in recent years.8–12 However, most photothermal agents are limited by their poor biocompatibility, larger size, superficial penetration depth and low photothermal conversion (PTC) efficiency.13 PTT reagents, which possess high PTC efficiency, can reduce the pain and treatment duration experienced by the patients.14 In addition, an appropriate imaging technique is in urgent demand to monitor the distribution of photothermal agents and to evaluate the therapeutic effect during therapy in vivo.13 Photoacoustic imaging (PAI), which can image tissue with a depth of 5–7 cm in a localized region,15–18 has higher resolution compared to other traditional optical imaging techniques. PAI is based on the detection of ultrasound waves generated from the thermally induced vibration and expansion of light absorbing tissues under specific pulsed laser irradiation.19,20 Furthermore, PAI has the ability to analyze nanomaterial accumulation and blood vessel distribution in tumors.21 Hence, the development of a PTT agent with intense NIR (700–1000 nm) absorption as well as PAI performance is necessary for cancer therapy.

Although a large number of NIR absorbing inorganic nanomaterials (such as Au, Ag, Pt, Pd, and C) have been explored for PTT,22–28 the potential toxicity and non-biodegradable nature of these inorganic nanostructures have seriously impeded their clinical application.28,29 To overcome these problems, a variety of organic photothermal agents have emerged, such as NIR dyes (ICG, IR-820, and IR-825) and RC-BSA.30–32 However, the low PTC efficiencies of these organic materials are not satisfactory for clinical application. Hence, the rational design and synthesis of effective PTT agents with higher PTC efficiency is in urgent need.

The diketopyrrolopyrrole (DPP) unit is an excellent electron acceptor due to its lactam structure, which has already been widely used in organic optical materials due to its excellent light absorption property.33–36 Recently, triphenylamine based thienyl-diketopyrrolopyrrole (DPP-TPA) with a donor–acceptor–donor (D–A–D) structure has shown great promise as a therapeutic agent for PTT with a PTC efficiency of 34.5% as reported by our group.35 To further improve the PTC efficiency, furyl-diketopyrrolopyrrole derivatives have come into our view. The steric hindrance of furyl-diketopyrrolopyrrole is smaller than that of thienyl-diketopyrrolopyrrole, and will result in better coplanarity.37,38 Furthermore, ferrocene (Fc), a cancer therapeutic agent itself, is introduced into the structure.39–41 As a good electron-donating unit, Fc can quench the fluorescence and singlet-oxygen (1O2) production through a photo-induced electron transfer (PET) process, enhancing the nonradiative transition of thermal energy release.41,42 Besides, it has been proven that iron-containing nanoparticles will be an extra boon for applications in PTT.43 Lastly, tetracyanobutadiene (TCBD), a strong electron acceptor unit, is introduced into the material system to build the D–A–D structure, which will give more red-shifted absorbance and promote the PET process.23,44–46

Herein, an excellent performance furyl-diketopyrrolopyrrole based PTT agent with a high molar extinction coefficient ε = 3.03 (±0.2) × 104 M−1 cm−1 (at 733 nm) and PAI effect in the form of nanoparticles has been designed and synthesized. The obtained Fc flanked DPP derivative with a TCBD unit (DPPCN-Fc, Scheme 2) shows intense NIR absorption for the PAI-guided PTT of cancer. To make the NIR absorbing DPPCN-Fc disperse in water, a re-precipitation method is applied to realize the hydrophilic DPPCN-Fc NPs.47 The as-prepared DPPCN-Fc NPs show amplifying PTC efficiency (η = 59.1%), superb stability, good biocompatibility, low dark cytotoxicity as well as excellent PAI property. The process of PET in the DPPCN-Fc molecule and a simplified representation of the PAI-guided PTT in vivo of DPPCN-Fc NPs are shown in Scheme 1. By carefully designing the structure, DPPCN-Fc NPs are expected to be a high performance therapeutic agent for photoacoustic imaging-guided cancer photothermal therapy.

image file: c7sc03351f-s1.tif
Scheme 1 A simplified representation of the photoacoustic imaging-guided photothermal therapy in vivo of DPPCN-Fc NPs.

Results and discussions

As shown in Scheme 2, DPPBr was synthesized in the presence of N-bromosuccinimide (NBS) in chloroform, then a Pd-catalyzed Sonogashira cross-coupling reaction was performed to prepare DPP-Fc in good yield. Subsequently, DPPCN-Fc was obtained by a [2 + 2] cycloaddition reaction with tetracyanoethylene (TCNE). All the intermediates and products were characterized by 1H NMR and 13C NMR. DPPCN-Fc was also characterized by MALDI-TOF-mass spectrometry (Fig. S1–S5). DPPBr, DPP-Fc and DPPCN-Fc are readily soluble in common organic solvents and the respective photographs in dichloromethane (DCM) under daylight are shown in Fig. 1a. The color changes from bluish violet to green. The green dye DPPCN-Fc was then conveniently self-assembled into nanoparticles through π–π stacking interactions and hydrophobic interactions by the re-precipitation method.47 The aqueous dispersion of the DPPCN-Fc nanoparticles is transparent as well (Fig. 1a), which indicates that the DPPCN-Fc NPs present excellent water solubility.
image file: c7sc03351f-s2.tif
Scheme 2 Synthetic route to DPPCN-Fc.

image file: c7sc03351f-f1.tif
Fig. 1 (a) Photographs of DPPBr, DPP-Fc, and DPPCN-Fc in DCM, and the DPPCN-Fc NPs in water. (b) A SEM image of the DPPCN-Fc NPs. Inset: a TEM image of a single DPPCN-Fc NP. (c) The DLS size distribution of the DPPCN-Fc NPs. (d) The normalized absorbance spectra of DPP-Fc, DPPCN-Fc in DCM, and the DPPCN-Fc NPs in water.

The size and morphology of the DPPCN-Fc NPs were characterized by scanning electron microscopy (SEM) and transmission electron microscopy (TEM) (Fig. 1b), which show well-defined spherical nanostructures. The dynamic light scattering (DLS) measurement further exhibits an average diameter of the DPPCN-Fc NPs as 80 ± 2.3 nm with a narrow size distribution (Fig. 1c). Fig. 1d shows that DPP-Fc presents a broad absorption band with λmax at 606 nm and DPPCN-Fc exhibits a broader absorption band in the visible-NIR region with λmax at 728 nm with a red-shift of 122 nm compared to DPP-Fc. This phenomenon comes from the fact that TCNE is a good electron-withdrawing unit, which can construct a D–A structure and push its absorbance to the biological window (700–1000 nm). Moreover, the DPPCN-Fc NPs in water also show a broad absorption band with λmax at 733 nm, caused by the strong π–π stacking interactions of DPPCN-Fc in the nanoparticle structure.47 In addition, the DPPCN-Fc NPs show a high molar extinction coefficient (ε = 3.03 (±0.2) × 104 M−1 cm−1, calculated by A = ε × C × L) at 733 nm (Fig. S6), which demonstrates the strong light absorption ability of the DPPCN-Fc NPs.

The intensive NIR absorption in the NIR region suggests that the DPPCN-Fc NPs would be an excellent photo-absorbing agent for PTT. To examine the photothermal effect of the DPPCN-Fc NPs, aqueous dispersions with different concentrations at 0, 20, 40, 60, 80, and 100 μg mL−1 were exposed to a 730 nm NIR laser at a power density of 1.0 W cm−2. As shown in Fig. 2a, the temperature increase of the DPPCN-Fc NPs is obviously concentration-dependent under laser irradiation. At the concentration of 100 μg mL−1, the temperature elevation is 33.4 °C. In comparison, no obvious temperature increase was observed for pure deionized water under the same conditions, demonstrating the excellent photothermal effect of the DPPCN-Fc NPs. When the DPPCN-Fc NP dispersion at a concentration of 80 μg mL−1 was exposed to a 730 nm NIR laser with power densities at 0.2, 0.4, 0.6, 0.8 and 1.0 W cm−2, the temperature increase showed an obvious laser power intensity dependence. At a power density of 1.0 W cm−2, the temperature elevation is 29.2 °C, as shown in Fig. 2c. Moreover, the infrared (IR) thermal images (Fig. 2b and d, recorded by an IR camera) show an obvious colour change from dark to white, which further confirms the excellent photothermal performance of the DPPCN-Fc NPs. All these results suggest that the DPPCN-Fc NPs are promising PTT agents with good PTC efficiency.

image file: c7sc03351f-f2.tif
Fig. 2 (a and c) The heating curves of the DPPCN-Fc NPs aqueous dispersions with different concentrations (0, 20, 40, 60, 80, and 100 μg mL−1) at a power density of 1.0 W cm−2 and various power densities (0.2, 0.4, 0.6, 0.8, and 1.0 W cm−2) at a concentration of 80 μg mL−1 (730 nm laser, 10 min). (b and d) The IR thermal images of the DPPCN-Fc NPs aqueous dispersions with various concentrations and power densities (730 nm laser, 10 min).

To further estimate the light-to-heat conversion of the nonradiative decay, the PTC efficiency (η) of the DPPCN-Fc NPs was calculated according to the equation described in the ESI. The temperature changes of the DPPCN-Fc NPs in the aqueous dispersion were recorded under 730 nm laser irradiation for 600 s and cooling for another 600 s. As a comparison, pure deionized water without the DPPCN-Fc NPs was also irradiated under the same conditions as a control, as shown in Fig. 3a and b. As a result, the PTC efficiency of the DPPCN-Fc NPs is calculated to be 59.1%, which is significantly higher than that of HMPBs (41.4%),48 RC-BSA nanoparticles (28.7%),31 TPT nanoparticles (32%),49 gold nanovesicles (37%),11 Au nanorods (21%),50 Cu9S5 (25.7%),14 and so on. Fig. 3c shows the light-to-heat cycle stability of the DPPCN-Fc nanoparticles. There is no decrease in the temperature elevation after four cycles of alternate heating (laser on: 5 min) and cooling (laser off: 5 min), which reveals that the DPPCN-Fc NPs have good photothermal stability. After the cycle measurements, the UV-vis-NIR spectrum of the DPPCN-Fc NP dispersion presents almost no obvious change in contrast to that before irradiation, as shown in Fig. 3d. In addition, we further characterized the size and morphology of the DPPCN-Fc NPs by SEM and TEM after laser irradiation to confirm the photostability. To verify whether the dispersant has an effect on the photostability, DPPCN-Fc NPs in phosphate buffer saline (PBS) were also studied. All the results showed that the nanoparticles retained their spherical nanostructures and size, which further revealed that the DPPCN-Fc NPs have excellent photostability in water and PBS (Fig. S7). The high PTC efficiency and superbly stable photothermal performance of the DPPCN-Fc NPs further makes them a promising photothermal agent for cancer PTT.

image file: c7sc03351f-f3.tif
Fig. 3 (a) The heating curve of the DPPCN-Fc NP aqueous dispersion in a procedure of laser-on and off for 20 min (pure water was irradiated as a control). (b) The linear cooling time data versus −ln(θ) obtained from the cooling period of (a). (c) The heating curve of the DPPCN-Fc NP aqueous dispersion at a concentration of 200 μg mL−1 during four cycles of on-and-off laser irradiation. (d) The UV-vis-NIR absorbance spectra of the DPPCN-Fc NPs before/after laser irradiation (730 nm, 1.0 W cm−2, 20 min).

The fluorescence decay profiles of DPPBr, DPP-Fc and DPPCN-Fc were measured via the time-correlated single photon counting (TCSPC) technique (Fig. S8a). Mono-exponential decays were observed for these three compounds, and the fluorescence lifetimes are 6.03, 2.08, and 0.17 ns, respectively. A similar result was observed regarding the fluorescence spectra of DPPBr, DPP-Fc and DPPCN-Fc, which show that the fluorescence of DPP-Fc and DPPCN-Fc is mostly quenched (Fig. S8b). The lifetime and fluorescence intensity descents of DPPCN-Fc reveal that the two Fc units can effectively quench the fluorescence of the center chromophore through a PET process. In addition, the 1O2 production of DPPBr, DPP-Fc and DPPCN-Fc in DCM was measured using 1,3-diphenylisobenzofuran (DPBF) as an indicator.34,51 At 411 nm, the degradation times of DPBF were 30 s and 15 min for DPPBr and DPP-Fc, respectively. However, the absorbance of DPBF in the DPPCN-Fc solution showed almost no degradation at 411 nm, even though the illumination time was extended up to 15 min (Fig. S8c). The longer degradation time of DPBF demonstrates that less 1O2 is generated by DPPCN-Fc via the ISC process. To further confirm the result in cancer cells (nuclei dyed with DAPI), fluorescence images were recorded using 2′,7′-dichlorofluorescein diacetate (DCFH-DA) as a probe to detect 1O2 generation in HeLa cells. As shown in Fig. S9, there is no 1O2 production after illumination for DPPCN-Fc, which further proves that the two Fc units can effectively quench 1O2 generation through a PET process.

According to these measurements and the result of the high PTC efficiency, a PET mechanism was proposed to better understand the amplifying photothermal property of the DPPCN-Fc NPs. As shown in Fig. 4, when DPPCN-Fc is excited from the ground state (S0) to the excited state (S1), this electron transfer is supposed to quench the S1 state to generate the charge transfer (CT) state. Once the CT state is produced, the electrons will transfer to the CT state, which will quench the radiative decay of fluorescence and release nonradiative energy as heat. In addition, the electrons will not jump to T1 through intersystem crossing (ISC), thereafter resulting in the low photosensitization property of 3O2 to 1O2.52

image file: c7sc03351f-f4.tif
Fig. 4 The proposed PET mechanism for the high PTC efficiency.

Encouraged by the outstanding PTC efficiency, the potential toxicity of the DPPCN-Fc NPs in vitro was further investigated by a cell viability MTT assay on HeLa cells first. It is well known that an ideal photothermal agent should be nontoxic or low-toxic in vitro or in vivo.14 As shown in Fig. 5a, the DPPCN-Fc NPs showed no dark cytotoxicity even at a high concentration (120 μg mL−1) after incubation for 24 h or even 48 h. Furthermore, the photothermal effect of the DPPCN-Fc NPs in vitro was tested by incubating HeLa cells with the DPPCN-Fc NPs and irradiating them under a 730 nm NIR laser. The viability of the HeLa cells declines with an increasing concentration of the DPPCN-Fc NPs. The 50% inhibitory concentration (IC50) is about 13 μg mL−1 (Fig. 5b). The cancer cell line A2780 was also operated as a parallel test, and the result is consistent with that in the HeLa cells. No dark toxicity and the high phototoxicity and good biocompatibility of the DPPCN-Fc NPs indicate that this material has great promise as an effective PTT agent for tumor therapy in vivo.

image file: c7sc03351f-f5.tif
Fig. 5 (a) The cell viability of HeLa cells incubated with the DPPCN-Fc NPs at different concentrations and times in dark conditions. (b) The cell viability of HeLa cells incubated with the DPPCN-Fc NPs without and with irradiation by a 730 nm laser (1.0 W cm−2, 3 min). (c) Confocal microscopy images of the HeLa cells incubated with the DPPCN-Fc NPs (80 μg mL−1) for 6 hours. The red and blue colours represent the fluorescence (excited at 488 nm) of the DPPCN-Fc NPs and DAPI images, respectively.

After confirming the advantages of the DPPCN-Fc NPs in the cellular microenvironment, the practical application for living-cell imaging was investigated, monitored by confocal microscopy after incubating the HeLa cells with the DPPCN-Fc NPs for 12 h and then staining with 4′,6-diamidino-2-phenylindole (DAPI) for nuclei imaging. Fig. 5c shows an obvious intra-cellular red fluorescence (excited at 488 nm). The overlay of the DPPCN-Fc NP fluorescence and nuclei staining indicates that the NPs are predominantly delivered to the cytoplasmic matrix of the cells. This result demonstrates that the DPPCN-Fc NPs present excellent cell uptake performance.

As the DPPCN-Fc NPs possess strong NIR absorption, they would be an excellent agent for PAI.53 As shown in Fig. 6a and b, the PA signal linearly increases with the increasing concentration of the DPPCN-Fc NPs. HeLa tumor-bearing mice were selected as the animal model for PAI in vivo, and were treated by intravenous injections with the DPPCN-Fc NPs (80 μg mL−1, 100 μL). Compared to the pre-injection image, the PA signals induced by the DPPCN-Fc NPs increased and reached a maximum at 6 h (Fig. 6c and d). Then the PA signals decreased gradually. This result indicates the efficient accumulation of the DPPCN-Fc NPs in the tumor site owing to the enhanced permeability and retention (EPR) effect,54 which reveals that the DPPCN-Fc NPs present a great prospect for PAI-guided PTT.

image file: c7sc03351f-f6.tif
Fig. 6 (a and b) The PA images and signal values of the DPPCN-Fc NP aqueous dispersions with different concentrations. (c and d) The PA images and signal values of the HeLa tumor on mice obtained at different times after i.v. injection of the DPPCN-Fc NPs (80 μg mL−1).

Motivated by the strong NIR optical absorption, amplifying photothermal performance and excellent PAI properties of the DPPCN-Fc NPs, the cancer photothermal therapy in vivo was measured with mice bearing HeLa tumours intravenously injected with the DPPCN-Fc NPs (100 μL, 80 μg mL−1) and saline (100 μL, as the control). After 6 h of injection, the tumors on these mice were exposed to a 730 nm laser at a power density of 1.0 W cm−2 for 8 min. Under irradiation, the tumor surface temperature increased rapidly (monitored by an IR thermal camera) within 8 min, as shown in Fig. 7a. This result can be attributed to the high tumor accumulation and the superb photothermal effect of the DPPCN-Fc NPs. In contrast, the tumor temperature without the DPPCN-Fc NP injection shows little change under the same irradiation conditions. To further estimate the PTT of the DPPCN-Fc NPs in vivo, HeLa tumor-bearing mice were randomly divided into 4 groups (n = 5): (i) saline without irradiation as the control group, (ii) saline with irradiation, (iii) the DPPCN-Fc NPs without irradiation, and (iv) the DPPCN-Fc NPs with irradiation as the treatment group. All the mice were treated by intravenous injection every two days.55 In the treatment group, all the tumours were completely ablated at the secondary treatment, then the black scars fell off at the tumor sites and no recurrence was observed. In marked contrast, the tumor volumes of all the mice in the other three groups reached up to 2000 mm3 within the life span of 18 days, as shown in Fig. 7b. The visual photograph of the therapeutic result is shown in Fig. 7d. The tumor of the treatment group was eliminated completely, suggesting the excellent photothermal effect of the DPPCN-Fc NPs.

image file: c7sc03351f-f7.tif
Fig. 7 (a) The IR thermal images of HeLa tumor-bearing mice with and without the DPPCN-Fc NPs (80 μg mL−1, 100 μL) under 730 nm laser irradiation at a power density of 1.0 W cm−2 for 8 min (6 h after injection). (b and c) The tumor volume and body weight changes of the four groups during treatment. Each data represents the mean of quintuplicate measurements. (d) Photographs of the HeLa tumor-bearing mice after treatment with the DPPCN-Fc NPs. (e) Photographs of the H&E stained tumor tissues obtained from the different groups after 18 days treatment.

Although the DPPCN-Fc NPs have no dark toxicity in vitro, the potential toxicity in vivo is still an important issue to be evaluated. As expected, no abnormalities in body weight (Fig. 7c), eating, drinking, urination and activity were observed during the whole treatment process. Furthermore, images of the major organs from the four groups by Hematoxylin and Eosin (H&E) staining were also recorded, and there are no abnormalities for these organs (heart, liver, spleen, lung, and kidney), as shown in Fig. S11. Moreover, the tumors of groups (i), (ii), and (iii) were also stained by H&E after the mice were sacrificed to investigate the therapeutic effects. The tumor cells of these three groups are arranged closely and the nuclei of the tumor cells are in good condition, as shown in Fig. 7e. All these results indicate little side effects and the minimally invasive character of the DPPCN-Fc NPs, which further confirms that the DPPCN-Fc NPs can be used as a potential therapeutic agent for PTT.


In conclusion, near-infrared DPPCN-Fc NPs have been designed and synthesized, in which two ferrocene units significantly quench the fluorescence and intersystem crossing because of photo-induced electron transfer (PET), which results in amplifying heat release. As a result, a high photothermal conversion efficiency of 59.1% was obtained. Furthermore, with the targeted accumulation of the DPPCN-Fc NPs in tumor tissues by the EPR effect in vivo, excellent PAI signals could be clearly observed at 6 hours after intravenous injection. The DPPCN-Fc NP agent showed an excellent cancer cell killing effect at injection doses as low as 0.4 mg kg−1 without any side effects in vivo. Accordingly, the as-prepared DPPCN-Fc NPs are a promising therapeutic agent for photoacoustic imaging-guided cancer photothermal therapy.

Conflicts of interest

The authors of this manuscript have no conflicts of interest.


The work was supported by the NNSF of China (61525402, 61775095, 61604071), Key University Science Research Project of Jiangsu Province (15KJA430006), and Natural Science Foundation of Jiangsu Province (BK20161012).


  1. M. Ferrari, Nat. Rev. Cancer, 2005, 5, 161–171 CrossRef CAS PubMed.
  2. N. Rozanova and J. Zhang, Sci. China, Ser. B: Chem., 2009, 52, 1559–1575 CrossRef CAS.
  3. H. Chen, F. Liu, Z. Lei, L. Ma and Z. Wang, RSC Adv., 2015, 5, 84980–84987 RSC.
  4. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit and R. Langer, Nat. Nanotechnol., 2007, 2, 751–760 CrossRef CAS PubMed.
  5. M. Ibrahim, R. Sabouni and G. A. Husseini, Curr. Med. Chem., 2017, 24, 193–214 CrossRef CAS PubMed.
  6. C. Wang, Y. Ye, G. M. Hochu, H. Sadeghifar and Z. Gu, Nano Lett., 2016, 16, 2334–2340 CrossRef CAS PubMed.
  7. C. Wang, W. Sun, Y. Ye, Q. Hu, H. N. Bomba and Z. Gu, Nat. Biomed. Eng., 2017, 1, 0011 CrossRef.
  8. J. Wang, R. Yan, F. Guo, M. Yu, F. Tan and N. Li, Nanotechnology, 2016, 27, 285102 CrossRef PubMed.
  9. M. Sun, F. Liu, Y. Zhu, W. Wang, J. Hu, J. Liu, Z. Dai, K. Wang, Y. Wei and J. Bai, Nanoscale, 2016, 8, 4452–4457 RSC.
  10. P. Huang, Y. Gao, J. Lin, H. Hu, H.-S. Liao, X. Yan, Y. Tang, A. Jin, J. Song and G. Niu, ACS Nano, 2015, 9, 9517–9527 CrossRef CAS PubMed.
  11. P. Huang, J. Lin, W. Li, P. Rong, Z. Wang, S. Wang, X. Wang, X. Sun, M. Aronova and G. Niu, Angew. Chem., 2013, 125, 14208–14214 CrossRef.
  12. X. Huang, P. K. Jain, I. H. El-Sayed and M. A. El-Sayed, Laser Med. Sci., 2008, 23, 217–228 CrossRef PubMed.
  13. S. Tang, M. Chen and N. Zheng, Nano Res., 2015, 8, 165–174 CrossRef CAS.
  14. Q. Tian, F. Jiang, R. Zou, Q. Liu, Z. Chen, M. Zhu, S. Yang, J. Wang, J. Wang and J. Hu, ACS Nano, 2011, 5, 9761–9771 CrossRef CAS PubMed.
  15. Q. Fan, K. Cheng, Z. Yang, R. Zhang, M. Yang, X. Hu, X. Ma, L. Bu, X. Lu and X. Xiong, Adv. Mater., 2015, 27, 843–847 CrossRef CAS PubMed.
  16. A. de la Zerda, S. Bodapati, R. Teed, S. Y. May, S. M. Tabakman, Z. Liu, B. T. Khuri-Yakub, X. Chen, H. Dai and S. S. Gambhir, ACS Nano, 2012, 6, 4694–4701 CrossRef CAS PubMed.
  17. Y.-S. Chen, W. Frey, S. Kim, P. Kruizinga, K. Homan and S. Emelianov, Nano Lett., 2011, 11, 348–354 CrossRef CAS PubMed.
  18. C. Kim, E. C. Cho, J. Chen, K. H. Song, L. Au, C. Favazza, Q. Zhang, C. M. Cobley, F. Gao and Y. Xia, ACS Nano, 2010, 4, 4559–4564 CrossRef CAS PubMed.
  19. K. Wilson, K. Homan and S. Emelianov, Nat. Commun., 2012, 3, 618 CrossRef PubMed.
  20. S. Mallidi, T. Larson, J. Tam, P. P. Joshi, A. Karpiouk, K. Sokolov and S. Emelianov, Nano Lett., 2009, 9, 2825–2831 CrossRef CAS PubMed.
  21. G. Wang, F. Zhang, R. Tian, L. Zhang, G. Fu, L. Yang and L. Zhu, ACS Appl. Mater. Interfaces, 2016, 8, 5608–5617 CAS.
  22. A. M. Gobin, E. M. Watkins, E. Quevedo, V. L. Colvin and J. L. West, Small, 2010, 6, 745–752 CrossRef CAS PubMed.
  23. D. Wang, Z. Guo, J. Zhou, J. Chen, G. Zhao, R. Chen, M. He, Z. Liu, H. Wang and Q. Chen, Small, 2015, 11, 5956–5967 CrossRef CAS PubMed.
  24. H. Bi, Y. Dai, J. Xu, R. Lv, F. He, S. Gai, D. Yang and P. Yang, J. Mater. Chem. B, 2016, 4, 5938–5946 RSC.
  25. M. Chen, S. Chen, C. He, S. Mo, X. Wang, G. Liu and N. Zheng, Nano Res., 2017, 1–15 CrossRef.
  26. J. T. Robinson, K. Welsher, S. M. Tabakman, S. P. Sherlock, H. Wang, R. Luong and H. Dai, Nano Res., 2010, 3, 779–793 CrossRef CAS PubMed.
  27. S. Zhang, K. Yang and Z. Liu, Sci. China: Chem., 2010, 53, 2217–2225 CrossRef CAS.
  28. N. Lewinski, V. Colvin and R. Drezek, Small, 2008, 4, 26–49 CrossRef CAS PubMed.
  29. L. Braydich-Stolle, S. Hussain, J. J. Schlager and M.-C. Hofmann, Toxicol. Sci., 2005, 88, 412–419 CrossRef CAS PubMed.
  30. X. Song, Q. Chen and Z. Liu, Nano Res., 2015, 8, 340–354 CrossRef CAS.
  31. B. Zhou, Y. Li, G. Niu, M. Lan, Q. Jia and Q. Liang, ACS Appl. Mater. Interfaces, 2016, 8, 29899–29905 CAS.
  32. F. Gao, L. Bai, X. Feng, H. P. Tham, R. Zhang, Y. Zhang, S. Liu, L. Zhao, Y. Zheng and Y. Zhao, Small, 2016, 12, 5239–5244 CrossRef CAS PubMed.
  33. Y. Cai, Q. Tang, X. Wu, W. Si, W. Huang, Q. Zhang and X. Dong, ChemistrySelect, 2016, 1, 3071–3074 CrossRef CAS.
  34. Y. Cai, Q. Tang, X. Wu, W. Si, Q. Zhang, W. Huang and X. Dong, ACS Appl. Mater. Interfaces, 2016, 8, 10737–10742 CAS.
  35. Y. Cai, P. Liang, Q. Tang, X. Yang, W. Si, W. Huang, Q. Zhang and X.-C. Dong, ACS Nano, 2017, 11, 1054–1063 CrossRef CAS PubMed.
  36. Y. Cai, W. Si, Q. Tang, P. Liang, C. Zhang, P. Chen, Q. Zhang, W. Huang and X. Dong, Nano Res., 2017, 10, 794–801 CrossRef CAS.
  37. H. Zhu, W. Huang, Y. Huang, J. Yang and W. Wang, Dyes Pigm., 2016, 127, 37–44 CrossRef CAS.
  38. E. Ripaud, D. Demeter, T. Rousseau, E. Boucard-Cétol, M. Allain, R. Po, P. Leriche and J. Roncali, Dyes Pigm., 2012, 95, 126–133 CrossRef CAS.
  39. X. J. Jiang, J. T. Lau, Q. Wang, D. K. Ng and P. C. Lo, Chem.–Eur. J., 2016, 22, 8273–8281 CrossRef CAS PubMed.
  40. C. Ornelas, New J. Chem., 2011, 35, 1973–1985 RSC.
  41. J. T. Lau, X.-J. Jiang, D. K. Ng and P.-C. Lo, Chem. Commun., 2013, 49, 4274–4276 RSC.
  42. J. F. Lovell, J. Chen, M. T. Jarvi, W.-G. Cao, A. D. Allen, Y. Liu, T. T. Tidwell, B. C. Wilson and G. Zheng, J. Phys. Chem. B, 2009, 113, 3203–3211 CrossRef CAS PubMed.
  43. S. Ghosh, T. Avellini, A. Petrelli, I. Kriegel, R. Gaspari, G. Almeida, G. Bertoni, A. Cavalli, F. Scotognella and T. Pellegrino, Chem. Mater., 2016, 4848–4858 CrossRef CAS.
  44. P. S. Bhale, H. V. Chavan, S. B. Dongare, S. N. Shringare, Y. B. Mule, S. S. Nagane and B. P. Bandgar, Bioorg. Med. Chem. Lett., 2017, 27, 1502–1507 CrossRef CAS PubMed.
  45. K. Li, L. Li, S. Wang, X. Li, T. Ma, D. Liu, Y. Jing and L. Zhao, Eur. J. Med. Chem., 2017, 126, 910–919 CrossRef CAS PubMed.
  46. B. Dhokale, T. Jadhav, S. M. Mobin and R. Misra, Dalton Trans., 2016, 45, 1476–1483 RSC.
  47. M. Lan, J. Zhang, X. Zhu, P. Wang, X. Chen, C.-S. Lee and W. Zhang, Nano Res., 2015, 8, 2380–2389 CrossRef CAS.
  48. X. Cai, X. Jia, W. Gao, K. Zhang, M. Ma, S. Wang, Y. Zheng, J. Shi and H. Chen, Adv. Funct. Mater., 2015, 25, 2520–2529 CrossRef CAS.
  49. T. Sun, J. Qi, M. Zheng, Z. Xie, Z. Wang and X. Jing, Colloids Surf., 2015, 136, 201–206 CrossRef CAS PubMed.
  50. Y. Chen, H. Chen, D. Zeng, Y. Tian, F. Chen, J. Feng and J. Shi, ACS Nano, 2010, 4, 6001–6013 CrossRef CAS PubMed.
  51. H. Shi, W. Sun, C. Liu, G. Gu, B. Ma, W. Si, N. Fu, Q. Zhang, W. Huang and X. Dong, J. Phys. Chem. B, 2016, 4, 113–120 CAS.
  52. H. Horiuchi, R. Kuribara, A. Hirabara and T. Okutsu, J. Phys. Chem. A, 2016, 120, 5554–5561 CrossRef CAS PubMed.
  53. X. Tan, J. Wang, X. Pang, L. Liu, Q. Sun, Q. You, F. Tan and N. Li, ACS Appl. Mater. Interfaces, 2016, 34991–35003 CAS.
  54. L. Cheng, K. Yang, Q. Chen and Z. Liu, ACS Nano, 2012, 6, 5605–5613 CrossRef CAS PubMed.
  55. S. Xu, Y. Yuan, X. Cai, C.-J. Zhang, F. Hu, J. Liang, G. Zhang, D. Zhang and B. Liu, Chem. Sci., 2015, 6, 5824–5830 RSC.


Electronic supplementary information (ESI) available: Experimental methods and additional figures. See DOI: 10.1039/c7sc03351f

This journal is © The Royal Society of Chemistry 2017